OVERVIEW

New Horizons in the Treatment of Relapsed and Refractory Myeloma is organized by Healthcare Made Practical (HMP) Communications LLC and will be held from Oct 31, 2018 - Oct 31, 2019.

Target Audience:
Designed for hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (e.g., physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Accreditation:
1.50 CME
1.50 CNE
1.50 CPE

Course Overview:
Multiple myeloma (MM) is an exceedingly challenging condition to treat, for many reasons. There is no cure for MM, and, even if achieved, complete response (CR) will ultimately fail over time. Relapsed/refractory (R/R) MM is treated with combination therapy, and the number of potential combinations can be daunting. Some randomized clinical trials (RCTs) are exploring optimal combination therapies for R/R MM, but, currently, data is sparse. With these challenges in mind, in this on-demand web archive, we focus on proteasome inhibitors (PIs), considered to be a backbone treatment of R/R MM, to better understand within-class differences and opportunities for synergistic combinations with other drugs to overcome these barriers.

Course Objectives:
• Identify patient factors that will influence the choice and sequencing of proteasome inhibitor combination medications for optimal individualized treatment of R/R MM
• Discuss proteasome inhibitor-based treatment approaches for multidrug-resistant R/R MM based on current data
• Evaluate emerging clinical trial data for novel combinations with proteasome inhibitors to overcome resistance in the management of R/R MM

Additional details will be posted as soon as they are available.